FindTrial
Sign In

To find role of nefopam in pain management and in improving quality of life during opioid withdrawal

ROLE OF NEFOPAM IN MANAGING PAIN IN PATIENTS OF OPIOID WITHDRAWAL AND IMPROVING THEIR SUBJECTIVE WELL BEINGâ??

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/02/031533
Enrollment
60
Registered
2021-02-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F112- Opioid dependence

Interventions

Intervention1: NEFOPAM: NEFOPAM GIVEN DAILY, ORALLY AT DOSE OF 30MG FOR 2 MONTHS Control Intervention1: IBUPROFEN: GIVEN DAILY ORALLY AT DOSE OF 400MG FOR 2 MONTH

Sponsors

Department of psychiatry
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. OPIOID DEPENDANCE AS PER ICD 10 2.Able to give informed consent

Exclusion criteria

Exclusion criteria: 1.HISTORY OF SEIZURES 2. HISTORY OF KIDNEY/LIVER/CARDIAC DISEASE 3.HISTORY OF BIPOLAR MOOD DISORDER

Design outcomes

Primary

MeasureTime frame
To study role of nefopam in managing pain in opioid withdrawalTimepoint: baseline, 2 weeks, 1 month and 2 months—

Secondary

MeasureTime frame
to study role of nefopam in improving the subjective well being 0f patientsTimepoint: baseline, 2 weeks,1 month and 2 months—

Countries

India

Contacts

Public ContactDR RAJNISH RAJ

GOVERNMENT MEDICAL COLLEGE AND RAJINDRA HOSPITAL PATIALA

profheadpsy@yahoo.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026